FDA Approves Vizz, First Prescription Eye Drop to Improve Near Vision for 10 Hours

The FDA has approved Vizz, a once-daily prescription eye drop, to temporarily improve age-related blurry near vision (presbyopia) for up to 10 hours. Developed by Lenz Therapeutics, Vizz works by narrowing the pupil, creating a "pinhole effect" that increases depth of focus without blurring distance vision. The drops are expected to be available starting in October and will be prescribed only. Common side effects include temporary dim vision, eye irritation, and headaches.

The U.S. Food and Drug Administration (FDA) has approved Vizz, a once-daily prescription eye drop developed by Lenz Therapeutics, to temporarily improve age-related blurry near vision (presbyopia) for up to 10 hours. Vizz contracts the iris sphincter muscle, creating a "pinhole effect" that increases depth of focus without blurring distance vision [2].

The approval, based on data from phase 3 studies, demonstrates Vizz's effectiveness in improving near vision within 30 minutes and maintaining the effect for up to 10 hours. No serious treatment-related adverse events were observed across all trials, with the most common side effects being mild, transient, and self-resolving, including installation site irritation, dim vision, and headache [2].

Vizz is expected to be available starting in October and will be prescribed only. The approval represents a significant advancement in treating presbyopia, offering a new treatment option for millions of people struggling with age-related near vision loss [2].

References:
[1] https://www.nature.com/articles/d41573-00138-3
[2] https://www.usnews.com/news/health-news/articles/2025-08-06/fda-approves-vizz-eye-drops-to-improve-near-vision-in-adults